Please login to the form below

Not currently logged in
Email:
Password:

KRAS

This page shows the latest KRAS news and features for those working in and with pharma, biotech and healthcare.

Boehringer links up with Trutino for cancer R&D

Boehringer links up with Trutino for cancer R&D

In September 2019, the German drugmaker also made a $720m play for a MEK inhibitor from India’s Lupin that it is looking to pair with its stable of KRAS inhibitors. ... Mutations in the KRAS pathway are involved in approximately a third of all cancers,

Latest news

More from news
Approximately 5 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The questions being asked are, what does an individual’s mutational profile look like, and do we have a drug to treat it; ie, do they have EGFR mutations, KRAS or

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

  • Pharma deals during September 2012 Pharma deals during September 2012

    advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics